Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.

ABSTRACT:

Background

Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for restless legs syndrome treatment in iron-deficient nonanemic patients.

Methods

Patients with moderate to severe restless legs syndrome and serum ferritin < 75 μg/L (or serum ferritin 75-300 μg/L and transferrin saturation < 20%) were randomized to ferric carboxymaltose (1000 mg iron) or placebo. Mean change difference between ferric carboxymaltose and placebo in International Restless Legs Syndrome Severity Scale score from baseline to week 4 was the primary end point; week 12 was a secondary end point.

Results

Ferric carboxymaltose treatment (n = 59) led to nonsignifi

SUBMITTER: Trenkwalder C 

PROVIDER: S-EPMC5655783 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature